Lv11
48 积分 2025-12-12 加入
一线免疫治疗失败的晚期食管鳞癌患者行免疫联合化疗与二线 化疗的疗效和安全性比较
2小时前
求助中
一线免疫治疗失败的晚期食管鳞癌患者行免疫联合化疗与二线 化疗的疗效和安全性比较
2小时前
已关闭
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept
1个月前
已完结
First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept
1个月前
已完结
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry
1个月前
已完结
THE ROLE OF PRETREATMENT EOSINOPHILIA TO PREDICT IMMUNE-RELATED ADVERSE EVENTS IN NSCLC PATIENTS ON IMMUNE CHECK POINT INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS
1个月前
已关闭
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
2个月前
已完结
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
2个月前
已完结
Mechanistic insights and therapeutic innovation in immune-related adverse events
2个月前
已完结
Trends in clinical development for PD-1/PD-L1 inhibitors
3个月前
已完结
皖公网安备34019202002308
